199 related articles for article (PubMed ID: 20534173)
1. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
Boroumand-Noughabi S; Sima HR; Ghaffarzadehgan K; Jafarzadeh M; Raziee HR; Hosseinnezhad H; Moaven O; Rajabi-Mashhadi MT; Azarian AA; Mashhadinejad M; Tavakkol-Afshari J
BMC Cancer; 2010 Jun; 10():275. PubMed ID: 20534173
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
Lim SC
Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.
Fathi M; Amirghofran Z; Shahriari M
Med Oncol; 2012 Sep; 29(3):2046-52. PubMed ID: 21528407
[TBL] [Abstract][Full Text] [Related]
4. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
5. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
6. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
7. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
8. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
Yuan BJ; Liu ZZ; Ding XR; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
[TBL] [Abstract][Full Text] [Related]
9. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
10. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Codony-Servat J; Garcia-Albeniz X; Pericay C; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Martínez-Cardús A; Martinez-Balibrea E; Maurel J
Med Oncol; 2013 Mar; 30(1):428. PubMed ID: 23338968
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
Musiał K; Zwolińska D
Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
Soni S; Rath G; Deval R; Salhan S; Mishra AK; Saxena S
Am J Reprod Immunol; 2011 Sep; 66(3):230-6. PubMed ID: 21385271
[TBL] [Abstract][Full Text] [Related]
16. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas/FasLare elevated in the serum and cerebrospinal fluid of patients with neurocysticercosis.
Chen X; Yu X; Wang Y; Zhu J; Gu J
Parasitol Res; 2017 Nov; 116(11):3027-3036. PubMed ID: 28965226
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
19. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
20. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
